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ABSTRACT 
 
Purpose: 
Epilepsy is a chronic neurological disorder that affects people of all age groups. 
Around 50 million people in the world have epilepsy, 5% to 10% of which live in 
India alone. 60% to 70% of people with epilepsy can be treated with 
simple monotherapy alone. The remaining patients require more than one drug for 
seizure control. But there is no consensus at present regarding the ideal 
Antiepileptic drug (AED) combinations. Our study examines epidemiological data, 
clinical characteristics of epilepsy, prescribing pattern of combination AEDs and 
their efficacy & adverse effect profile. 
 
Methods: 
200 patients with epilepsy attending the Epilepsy clinic of the Institute of 
Neurology, Madras medical college & Rajiv Gandhi Govt. General Hospital, 
Chennai, who were on AED polytherapy were included in the study after getting 
informed written consent. Complete history and physical examination were noted. 
Medication history was obtained from old records. Investigation reports were gone 
through. 
 
Results: 
Majority was middle aged, educated (65.5%) and employed (81.5%) males 
(61.5%). Idiopathic generalized seizures were more common (61%) than partial 
seizures. Structural lesions were present in 16.5% of patients and they had poor 
seizure control. More than half of the patients were treated with two drug AED 
combinations. 56.5% of patients were maintained on double drug combinations, 
39.5% on three drug and 4% on four drug combinations. No combination had more 
than four drugs. Phenytoin was the commonly used antiepileptic drug in various 
combinations. Phenytoin and Carbamazepine were the commonly used double 
AED combination regimen. Phenytoin, Carbamazepine and Sodium valproate were 
the commonly used three drug AED combination regimen. Antiepileptic drugs of 
choice for generalized seizures and partial seizures were used in accordance with 
the recommended guidelines.  Overall, 54% of patients had good seizure control 
with the combination AEDs.  50% of patients reported at least one minor adverse 
event, which did not require change of drugs. Adverse events were more common 
with three and four drug combinations than two drug combinations. 
 
Conclusion: 
Efficacy of conventional AED combinations in controlling seizures was 
comparable to newer antiepileptics. In cost constrained situations older AEDs are 
as effective as newer and more costly AEDs. Though AEDs with similar 
mechanisms of action are generally not preferred due to the concern of additive 
side effects, in our study they were as effective as other combinations with 
different mechanisms of action. The adverse events were also comparable. Seizure 
control was better with two drug combinations than that of three and four drug 
combinations. Though monotherapy should be tried as for as possible, 
polytherapy remains the mainstay of treatment for large proportion of epileptic 
patients, particulalrly in cases of refractory epilepsy. Rational ploytherapy is a 
difficult to achieve goal with the knowledge available at present. It needs further 
research to find the ideal AED combinations. Treatment decision has to be made 
on an individual basis to make the polytherapy a successful one. 
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Introduction 
Epilepsy is a chronic neurological disorder that affects people of all ages. 
Around 50 million people in the world have epilepsy.
1
 5% to 10% of which, i.e. 
5-10 million people live with epilepsy in India alone.
2
 
60% to 70% of people with epilepsy can be treated with simple monotherapy 
alone. The remaining patients require more than one drug for seizure control. 
But there is no consensus at present regarding the ideal Antiepileptic drug 
(AED) combinations. 
Antiepileptic drugs act through many different mechanisms. By logical 
reasoning we can assume that combining drugs acting through same mechanism 
will lead to additive side effects. Hence it is reasonable to combine drugs with 
different mechanisms of action, particularly combining one drug having 
multiple mechanisms of action with another drug having single mechanism of 
action. This has been proven consistently in the synergistic combination of 
Valproic acid with lamotrigene. 
More than 20 antiepileptic drugs are available in the market today. So selecting 
the combination will be a daunting task. However, when chosen carefully, 
combination AEDs may have synergistic efficacy with low adverse effects. Still 
further research is needed to identify the ideal combination. 
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Aim of the study 
 
 To analyze the epidemiological data, clinical characteristics of epilepsy, 
prescribing pattern of combination antiepileptic drugs in a tertiary care 
hospital in Chennai 
 To analyze the efficacy and adverse effect patterns of combination 
antiepileptic drugs. 
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Review of literature 
Epilepsy is a chronic neurological disorder that affects people of all ages. 
According to WHO around 50 million people in the world have epilepsy.
1
 Among 
them, developing countries contribute to nearly 80%. There may about 5-10 
million people with epilepsy in India, which roughly corresponds to 0.5 – 1.0 % of 
the population.
2
 Majority of people with epilepsy can be treated with simple drugs. 
Though Epilepsy responds to treatment in about 70%, three fourths of Epileptics in 
the developing countries do not get the treatment they need. Stigma and 
discrimination affects people with epilepsy and their families in many parts of the 
world, particularly in developing countries. The financial burden of treating 
epilepsy is enormous. 
Definitions 
Seizure 
The International League Against Epilepsy (ILAE) defines epileptic seizure as ‘‘a 
transient occurrence of signs and/or symptoms due to abnormal excessive or 
synchronous neuronal activity in the brain’’3. The epileptic seizure may be 
characterized by motor, sensory, autonomic or psychic phenomena with or without 
loss of consciousness.
2
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Epilepsy 
Epilepsyis a disorder of the brain characterized by an enduring predisposition to 
generate epileptic seizures, and by the neurobiological, cognitive, psychological, 
and social consequences of this condition. The definition of epilepsy requires the 
occurrence of at least one epileptic seizure. 
 
The revised ILAE Operational (Practical) Clinical Definition of Epilepsy 
3
states thatEpilepsy is a disease of the brain defined by any of the following 
conditions:  
1. At least two unprovoked seizures occurring more than 24 hours apart.  
2. One unprovoked seizure and a probability of further seizures similar to the 
general recurrence risk after two unprovoked seizures (approximately 75% or 
more).  
3. At least two seizures in a setting of reflex epilepsy.  
Epilepsy is considered to be no longer present for individuals who had an age-
dependent epilepsy syndrome but are now past the applicable age or those who 
have remained seizure-free for at least 10 years off anti-seizure medicines, 
provided that there are no known risk factors associated with a high probability 
(>75%) of future seizures. 
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Drug Resistant Epilepsy 
Drug resistant epilepsy may be defined as failure of adequate trials of two tolerated 
and appropriately chosen and used AED schedules (whether as monotherapies or in 
combination) to achieve sustained seizure freedom.
4
 
 
Seizure freedom 
Freedom from all types of seizures for 12 months or three times the 
preinterventioninterseizure interval, whichever is longer.
4
 
 
Classification of Seizures and Epilepsy: 
Seizures and Epilepsy are classified by the International League Against Epilepsy 
by the two major schemes namely, International Classification of Epileptic 
Seizures (1981), and International Classification of Epilepsies and Epilepsy 
Syndromes (1989). 
The concepts, terminology, and approaches for classifying seizures and epilepsy 
were revised by the ILAE Commission on Classification and Terminology (2010)
5
. 
However older classification systems are still continued to be used in wider clinical 
practice. 
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Classification of Seizures: 
The 1981 classification dichotomized seizures as generalized and focal according 
to the extent of spread. Generalized seizures involve bilaterally distributed 
networks, whereas focal seizures spread within networks limited to one 
hemisphere. Table 1 shows classification scheme for Seizures.
6
 
Table. 1 
ILAE Classification of Epileptic Seizures 
I. Partial (Focal, Local) Seizures 
A. Simple partial seizures (consciousness not impaired) 
1. With motor symptoms 
2. With somatosensory or special sensory symptoms 
3. With autonomic symptoms 
4. With psychic symptoms 
B. Complex partial seizures (with impairment of 
consciousness) 
1. With simple partial onset followed by impairment of 
consciousness 
2. With impairment of consciousness at onset 
C. Partial seizures evolving to secondarily generalized seizures 
1. Simple partial seizures evolving to generalized seizures 
2. Complex partial seizures evolving to generalized 
seizures 
3. Simple partial seizures evolving to complex partial seizures 
evolving to generalized seizures 
12 
 
 
II. Generalized Seizures (Convulsive or Nonconvulsive) 
A. Absence seizures 
1. Typical absence seizures 
2. Atypical absence seizures 
B. Myoclonic seizures 
C. Clonic seizures 
D. Tonic seizures 
E. Tonic-clonic seizures 
F. Atonic seizures 
III. Unclassified Epileptic Seizures 
 
 
Classification of Epilepsies and Epileptic Syndromes: 
1989 ILAE Classification of Epilepsies and Epileptic syndromes has two important 
divisions. They first separated the generalized from localization related epilepsies. 
The other division separated epilepsies of known etiology (symptomatic) from 
unknown etiology. Epilepsies of unknown etiology were called idiopathic if there 
is no underlying cause could be found and considered to be genetic, or cryptogenic 
if occult underlying cause is suspected. Table 2 shows classification scheme for 
epilepsies and epileptic syndromes
7
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Table. 2 
ILAE Classification of Epilepsies and Epileptic Syndromes
 
1. Localization-related (focal, local, partial) epilepsies and 
syndromes 
1.1. Idiopathic (with age-related onset) 
1.2. Symptomatic 
1.3. Cryptogenic 
2. Generalized epilepsies and syndromes 
2.1. Idiopathic (with age-related onset, listed in order of age 
appearance) 
2.2. Cryptogenic or symptomatic (in order of age) 
2.3. Symptomatic 
2.3.1. Nonspecific etiology 
2.3.2. Specific syndromes 
3. Epilepsies and syndromes undetermined as to whether they 
are focal or generalized 
3.1. With both generalized and focal seizures 
3.2. Without unequivocal generalized or focal features 
4. Special syndromes 
4.1. Situation-related seizures (Gelegenheitsanfälle) 
4.1.1. Febrile convulsions 
4.1.2. Isolated seizures or isolated status epilepticus 
4.1.3. Seizures occurring only when there is an acute 
metabolic or toxic event 
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Pathophysiology of Epilepsy: 
Basic Mechanisms of Focal Seizure Initiation and Propagation
8
 
During a seizure, hypersynchronus discharges may begin in a very discrete region 
of cortex and then spread to neighboring regions. Seizure initiation is characterized 
by two concurrent events:  
1) high-frequency bursts of action potentials which lead to influx of 
extracellular Ca
++
, which results in the opening of voltage-dependent Na
+
 channels. 
This leads to influx of Na
+
, and generation of repetitive action potentials. 
Depending on the cell type, the subsequent hyperpolarizing afterpotential is 
mediated by either GABA receptors andCl
−
 influx, or by K
+
 efflux. 
2) hypersynchronization of a neuronal population: When there is sufficient 
activation to recruit surrounding neurons, a partial seizure spreads within the brain 
by the process known as Seizure propagation. This leads to a loss of surround 
inhibition, which results in the spread of seizure activity into contiguous areas via 
local cortical connections, and to more distant areas via long association pathways 
such as the corpus callosum. 
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Epileptogenesis: The Transformation of a Normal Network Into a 
Hyperexcitable Network
8
 
Patients with head injury usually do not present with seizures for months or years. 
This "silent period" after the initial injury shows that there is gradual 
transformation of the neural network to evolve into epileptogenic focus over time. 
Changes that occur during silent period could include delayed necrosis of 
inhibitory interneurons (or the excitatory interneurons driving them), or sprouting 
of axonal collaterals leading to reverberating, or self-reinforcing, circuits, Which 
results in long-lasting biochemical and/or structural changes in the CNS. However, 
the exact mechanisms underlying kindling, and its applicability to human 
epileptogenesis, remain unknown. 
 
Pharmacotherapy: 
The goal of pharmacological treatment of epilepsy is to obtain seizure control 
without adverse effects. Though idiopathic (primary) generalized epilepsies 
respond well to AEDs, 40% of patients with focal seizures related to structural 
lesions continue to have seizures even with optimal AED therapy. In them, atleast 
a balance between seizures and medication related side effects is expected. 
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Pharmacology of Antiepileptic drugs 
Selection and optimization of AED therapy requires not only an understanding of 
drug mechanism of action and spectrum of clinical activity but also of 
pharmacokinetic variability and of particular drug related adverse events. 
 
Nearly 14 antiepileptic drugs (AEDs) have been licensed for use in the past 20 
years  for common epilepsies and a range of more unusual syndromes. AEDs are 
classified into first, second and third generation drugs according to the year of 
entry into the market 
 
Table. 3  
First generation Second generation Third generation 
Phenytoin 
Carbamazepine 
Phenobarbitone 
Sodium Valproate 
Benzodiazepine 
Ethosuximide 
Gabapentin &Pregabalin 
Lamotrigine 
Levetiracetam 
Topiramate 
Oxcarbazepine 
Tiagabine 
Felbamate 
Vigabatrin 
Lacosamide 
Rufinamide 
Eslicarbazepine Acetate 
Retigabine 
Brivaracetam 
Perampanel 
Ganoxolone 
Carabersat 
17 
 
Zonisamide 
Fosphenytoin 
Carisbamate 
DP Valproic acid 
Fluorofelbamate 
Losigamone 
Remacemide 
Safinamide 
Seletracetam 
Stiripentol 
Talampanel 
 
Mechanism of action of AEDs 
AEDs act on ion channels located at the cell membrane to exert their antiseizure 
effects.  Though these agents increase the threshold level for seizure, they have no 
effect on epileptogenesis.
9
 
 
Table.4 
Primary mechanism(s) of action of common AEDs
10
 
Sodium channel blockers 
     (a) Fast-inactivated state—phenytoin, carbamazepine, lamotrigine, 
oxcarbazepine,eslicarbazepine 
     (b) Slow-inactivated state—lacosamide 
18 
 
Calcium channel blockers 
     (a) Low voltage activated channel—ethosuximide 
     (b) High voltage activated channel—gabapentin, pregabalin 
GABA-ergic drugs 
     (a) Prolongs chloride channel opening—barbiturates 
     (b) Increased frequency of chloride channel opening—benzodiazepines 
     (c) Inhibits GABA-transaminase—vigabatrin 
     (d) Blocks synaptic GABA reuptake—tiagabine 
Synaptic vesicle protein 2A modulation—levetiracetam 
Carbonic anhydrase inhibition—acetazolamide 
Multiple pharmacological targets—sodium valproate, felbamate, topiramate, 
zonisamide, rufinamide 
 
In general, AEDs are better tolerated when started at low dose and gradually 
increased to the maximum dose.  
The following table briefly mentions the starting and maintenance doses of 
commonly used AEDs 
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Table.5 
 
Initial and maintenance daily doses, primary mode(s) of action and primary 
indications of commonly used AEDs
2,11
 
AED Starting 
dose in 
average 
adult 
Maintenance 
dose in 
average 
adult 
(mg/day) 
Primary mode(s) 
of action 
Indications 
(Seizure 
types/syndrome) 
Carbamazepine 
(CBZ) 
 
100 mg 
BID 
400 -1000 Blocks fast-
inactivated state of 
Na
+
 channel 
Partial, GTCS 
Clobazam 
(CLB) 
10 mg 
OD (HS) 
10-30 Activates GABAA 
receptor 
Partial, GTCS 
Lamotrigine 
(LTG) 
 
25 mg 
OD (HS) 
Lower 
dose 
with 
VPA 
100-300 Blocks fast-
inactivated state of 
Na
+
 channel/other 
mechanisms 
Partial, GTCS 
Levetiracetam 
(LEV) 
250 mg 
BID 
1000-3000 Modulates 
synaptic vesicle 
protein 2A 
Partial, GTCS 
Oxcarbazepine 
(OXC) 
150 mg 
BID 
600-1800 Blocks fast 
inactivated state of 
Na
+
 channel 
Partial, GTCS 
Phenobarbitone 
(PB) 
60-90 
mg 
OD (HS) 
60-180 Activates GABAA 
receptor 
Partial, GTCS, 
myoclonic, tonic, 
clonic, SE 
Phenytoin 
(PHT) 
200-300 
mg 
OD (HS) 
200-400 Blocks fast-
inactivated state of 
Na
+
 channel 
Partial, GTCS, 
SE 
20 
 
Topiramate 
(TPM) 
 
25 mg 
OD 
100 – 400 Various actions on 
multiple targets 
Partial, GTCS, 
myoclonic, 
Lennox–Gastaut 
Valproate 
(VPA) 
 
200 mg 
BID 
 
500-2000 Various actions on 
multiple 
Targets 
Partial, GTCS 
Zonisamide 
(ZNS) 
50 mg 
OD (HS) 
200-500 Various actions on 
multiple 
Targets 
Partial, GTCS 
 
Adverse effects of AEDs  
Dose related adverse effects of AEDs can be managed by appropriate maintenance 
of serum drug concentrations. Also early identification of idiosyncratic AEs which 
poses significant health issues for PWE can be lifesaving. Drug interactions can be 
assessed by their pharmacokinetics and pharmacodynamic properties. Hepatic 
enzyme systems may facilitate AED interaction with other co administered 
medication through induction or inhibition of drug metabolism and result in AEs or 
seizures. Nearly 25% of patients become defaulters due to adverse effects with the 
initial AED chosen, and up to one-third are refractory despite repeated AEDs, 
potentially leading to recurrent adverse events and drug interactions.
12
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Table. 6 
Antiepileptic Drugs and Their Common Acute, Chronic, and Idiosyncratic 
AdverseEffects
12
 
Antiepileptic 
Drug 
Acute Adverse 
Effects 
Chronic Affects Idiosyncratic 
Affects 
Phenobarbital 
(PB)/ 
primidone 
(PRM) 
Sedation, fatigue, 
ataxia, 
blurry vision 
Hyperactive 
(children), 
learning, 
depression 
Rash, connective-
tissue 
disorders, 
hepatoxicity 
Phenytoin 
(PHT) 
Somnolence, 
dizziness, 
ataxia, blurry vision, 
N 
 
Neuropathy, gum 
hyperplasia, 
hirsutism, 
low thyroid, 
osteoporosis 
 
SJS, lupuslike 
reactions, 
pseudolymphoma, 
hepatitis, blood 
dyscrasias 
Ethosuximide 
(ETH) 
 
Somnolence, 
N/V/diarrhea, 
dizziness, anorexia, 
abdominal pain 
Behavioral 
changes, 
irritability, 
nervousness, 
confusion, 
psychosis 
 
SJS, lupuslike 
reaction, 
blood dyscrasias, 
hepatoxicity, 
generalized Sz 
increase 
Carbamazepine 
(CBZ) 
Somnolence, fatigue, 
rash, diplopia, 
dizziness, 
Behavioral 
changes, 
low sodium, 
SJS, hepatoxicity, 
aplastic 
anemia/low white 
22 
 
ataxia, N/V weight 
gain/edema 
blood 
cell count 
Valproic acid 
(VPA) 
 
Abdominal pain, 
N/V/ 
diarrhea, 
hyperammonemia 
Tremor, alopecia, 
amenorrhea, 
weight gain 
 
Liver/pancreatic 
failure, 
low platelets, birth 
defects 
Felbamate 
(FBM) 
Headache, N/V, rash Anorexia, weight 
loss, insomnia 
SJS, aplastic 
anemia, 
hepatic failure 
Gabapentin 
(GBP)/ 
pregabalin 
(PGB) 
Somnolence, fatigue, 
ataxia, 
dizziness, blurry 
vision 
Weight gain, 
pedal edema, 
behavior changes 
(children), 
creatine 
phosphokinase 
None established 
 
Lamotrigine 
(LTG) 
Dizziness, diplopia, 
blurry vision, N/V, 
ataxia 
Headache, 
insomnia, 
incoordination, tic 
SJS, TEN, DRESS, 
myoclonic Sz 
increase 
Topiramate 
(TPM) 
Somnolence, 
dizziness, 
fatigue, anorexia, N 
Mental slowing, 
speech 
and memory 
disturbance, 
paresthesias, 
weight 
loss, renal stones 
Hepatic failure, 
oligohidrosis, 
glaucoma 
 
Tiagabine Headache, dizziness, Abnormal Nonconvulsive 
23 
 
(TGB) fatigue, 
N/V, abdominal pain 
thinking, 
tremor, 
nervousness 
spike-wave stupor 
Oxcarbazepine 
(OXC) 
 
Somnolence, 
dizziness, 
fatigue, N/V 
 
Hyponatremia 
(elderly), 
insomnia, 
headache 
SJS, TEN 
 
Levetiracetam 
(LEV) 
Somnolence, 
dizziness, 
fatigue, N 
Irritability, anger, 
anxiety, 
depression 
None established 
 
Zonisamide 
(ZNS) 
 
Somnolence, ataxia, 
N/V, 
dizziness, fatigue 
 
Lost appetite, 
speech, 
paresthesias, 
weight loss, 
renal stones, 
apathy 
Rash, 
hypersensitivity 
reactions (sulfa) 
 
Rufinamide 
(RUF) 
Somnolence, N/V, 
headache, 
dizziness, fatigue 
Incoordination, 
ataxia, 
shortened QT 
interval 
Rash, DRESS 
Lacosamide 
(LCS) 
Somnolence, 
dizziness, N, 
fatigue, diplopia 
 
Headache, tremor, 
ataxia, 
incoordination, 
depression 
None established 
 
Vigabatrin 
(GVG) 
Somnolence, 
dizziness, fatigue 
blurred vision, 
arthralgia 
Permanent visual 
field 
24 
 
 Weight gain, 
edema, 
neuropathy, 
depression 
loss, psychosis 
 
N = nausea; V = vomiting; Sz = seizure; DRESS = drug reactions with eosinophilia 
and systemic symptoms; TEN = toxic epidermal necrolysis; SJS = Steven-Johnson 
syndrome. 
General Approach to Treatment 
Regarding the initiation of pharmacologic therapy the recent 2012 NICE (National 
Institute of Health and Care Excellence) guidelines, which was updated in 
December 2013 says that
13
 
 AED therapy should be started only after the diagnosis of epilepsy is 
confirmed. 
 Treatment with AED is generally recommended after a second seizure. 
However in conditions where the individual has a neurological deficit, the 
EEG shows unequivocal activity and a structural abnormality is seen in the 
brain, AEDs may be started after the first seizure.  
 The decision to initiate AED therapy should be taken after a full discussion 
with the patient, their relatives about the risks and benefits. 
 Individuals should be treated with a single antiepileptic drug (Monotherapy) 
wherever possible. If the initial treatment is unsuccessful, then monotherapy 
25 
 
using a second drug can be tried. If an AED has failed due to adverse effects 
or continued seizures, then a second drug is started (which is an alternative 
first line or second line drug) and built up to an adequate or maximum 
tolerated dose; then the first drug is slowly tapered. 
 It is recommended that only when attempts at monotherapy with AEDs have 
failed, combination AED therapy (adjunctive or add on therapy) should be 
considered. 
 Combination of drugs with different mechanisms of action is considered 
advantageous. 
 
When to stop AEDs? 
There are no well accepted guidelines regarding the time at which AEDs can be 
stopped. However with available studies it has been possible to withdraw the 
AEDs in many patients who have been seizure free for 2 to 5 years.
14
  The benefits 
associated with discontinuation of AEDs must be weighed against the possibility 
that a seizure may recur again. In 26 to 63% of adults, relapse occurs within one to 
two years after AED withdrawal.
9
 Predictors of relapse include an abnormal EEG 
prior to or during medication withdrawal, abnormal neurological exam, mental 
retardation, and frequent seizures prior to withdrawal. Successful AED withdrawal 
in adults is more likely after a longer seizure free period. However, there are a few 
26 
 
epilepsy syndromes for which the chance of recurrence is so high that AED 
discontinuation is not suggested. These include juvenile myoclonic epilepsy and 
reading epilepsy.
15
  Medication withdrawal should not proceed faster than a 20% 
dose reduction every five half-lives unless there is a definite need for more rapid 
discontinuation.  
 
Selection of AEDs 
For initial monotherapy of partial seizures, high-level of evidence exists for the 
efficacy of carbamazepine, oxcarbazepine, and topiramate and for initial 
monotherapy of generalized seizures, high-level evidence is available for 
valproate, lamotrigine, topiramate, and oxcarbazepine.  
 
For initial monotherapy of absence seizures, high level evidence exists for 
valproate, lamotrigine, and ethosaximide.
16
 All second generation AEDs have 
efficacy as adjunctive therapy for partial seizures.  
 
AEDs should be selected on the basis of comorbid conditions, including 
depression, migraine, chronic pain, obesity, and nephrolithiasis, or patient 
characteristics, especially for women of childbearing potential and older adults, as 
27 
 
AEDs are often useful for comorbid conditions or have properties that should be 
avoided in some groups. 
Table.7 
AEDs : Level of evidence for each seizure type and epilepsy syndrome
17
 
Seizure type or epilepsy syndrome Level of efficacy and effectiveness 
evidence (in alphabetical order) 
Adults with partial-onset seizures Level A: CBZ, LEV, PHT, ZNS 
Level B: VPA 
Level C: GBP, LTG, OXC, PB, TPM, 
VGB 
Level D: CZP, PRM 
Children with partial-onset seizures Level A: OXC 
Level B: None 
Level C: CBZ, PB, PHT, TPM, VPA, 
VGB 
Level D: CLB, CZP, LTG, ZNS 
Elderly adults with partial-onset 
seizures 
Level A: GBP, LTG 
Level B: None 
Level C: CBZ 
Level D: TPM, VPA 
Adults with generalized onset tonic–
clonic seizures 
Level A: None 
Level B: None 
Level C: CBZ, LTG, OXC, PB, PHT, 
TPM, VPA 
Level D: GBP, LEV, VGB 
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Children with generalized-onset 
tonic–clonic seizures 
Level A: None 
Level B: None 
Level C: CBZ, PB, PHT, TPM, VPA 
Level D: OXC 
Children with absence seizures Level A: ESM, VPA 
Level B: None 
Level C: LTG 
Level D: None 
Benign epilepsy with centrotemporal 
spikes (BECTS) 
Level A: None 
Level B: None 
Level C: CBZ, VPA 
Level D: GBP, LEV, OXC, STM 
Juvenile myoclonic epilepsy (JME) Level A: None 
Level B: None 
Level C: None 
Level D: TPM, VPA 
 
Monotherapy or Polytherapy? 
Until the early 80’s, polytherapy was widely practiced as first line treatment for 
refractory epilepsy with the hope that there will be less severe drug toxicity when 
two drugs with lower doses are combined.
18
 Subsequent trials by Shorvon& 
Reynolds (1979) and Schmidt (1983) lead to a change  from monotherapy to 
polytherapy.
19
 
 
29 
 
Up to 2/3 of patients respond initially to single AED; approximately 47% respond 
to the initial AED, if they don’t respond, substitution of a second AED may benefit 
another 13% of patients.
20
 If those two drugs do not control seizure, there is only 
small chance of success with further monotherapy trials. The remaining patients 
require more than one AED for seizure control.
21
 
 
With the addition of more than 14 new drugs over the past two decades, the 
combinations and permutations became numerous (200 double drug combinations 
or more than 1000 triple drug combinations). 
 
The clinical effects of two drugs, when a second drug being added to a patient on 
monotherapy could result in three outcomes:  
(1)Additive  
(2)Supra-additive or  
(3)Infra-additive or antagonistic 
 
For better clinical outcome, regarding clinical effectiveness, synergy (at least 
additivity) is desirable; for adverse effects, antagonism is preferable.The following 
table lists some of the favourable and unfavourable AED combinations 
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Table.8
18
 
Favourable AED combinations 
CBZ GBP, LEV, OXC, TPM, VPA 
CZP OXC 
ESX VPA 
FBM  LEV, LTG, TPM  
GBP  LEV, LTG, OXC, PB, PHT, TGB, TPM, VIG, VPA 
LEV  CBZ, FBM, OXC, PB, TPM  
LTG  FBM, GBP, TPM, VPA  
OXC  CBZ, CZP, GBP, LEV, TPM 
PB  GBP, LEV, PHT 
PHT  GBP, PB, VPA 
TGB  GBP, VIG, VPA 
TPM  CBZ, FBM, GBP, LEV, LTG, OXC, VPA 
VIG  GBP, TGB 
VPA   
 
CBZ, ESX, GBP, LTG, PHT, TGB, TPM 
Unfavourable AED combinations  
CBZ  LTG 
CZP  FBM 
FBM  CBZ, OXC, TGB, VPA 
LTG  CBZ, OXC 
OXC  FBM, LTG, PHT 
PHT  OXC  
TGB  FBM 
VPA  FBM 
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Although it’s not possible always to have combination with synergistic clinical 
effect and antagonistic adverse effects all the times, it might be acceptable to have 
a drug combination with intermediate effects, i.e., additive with regard to their 
clinical effect but antagonistic with regard to their side effects or  two drugs that 
are synergistic clinically but only additive adverse effects. 
 
Clinical considerations inPolytherapy 
The choice of optimal polytherapy is difficult for many reasons. Foremost among 
them is, the availability of very limited data regarding the favourable or 
unfavourablecombinaitons. Also, there is only very little systematic evidence 
available as any one combination is more or less effective than others.
18
 
 
Combination therapy with different mechanisms of action has been generally 
preferred since theoretically small effects on multiple drug targets may be more 
effective than drugs acting on single mechanism of action. Studies have shown that 
the combination of sodium channel blockers, Phenytoin and Carbamazepine, is less 
effective than with either in combination with Phenobarbitone.
22
 Drugs with 
similar mechanism action may have similar side effect profiles, resulting in 
additive side effects in such combinations. Some studies have shown that even 
drugs with similar mechanisms of action such as Phenytoin and Carbamazepine 
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produce different adverse effect profiles.
23
 Furthermore, combination of two drugs 
with completely different mechanisms of action may have similar side effects by 
acting upon unidentified targets which not related to their antiepileptic 
mechanisms.
24
 
 
In summary, there is insufficient evidence at present to provide meaningful 
guidelines to determine whether similar or different mechanism of action should be 
targeted for rational combination of AEDs. This appears true for both efficacy and 
adverse effect profile. Nonetheless, two AEDs with virtually identical mechanisms 
of actions should be avoided to minimize adverse effects.  
 
Guidance for combining Antiepileptic drugs 
While rational polytherapy remains an elusive goal, guidelines for the approach to 
monotherapy should also apply for combinations of AEDs, although there would 
potentially be exaggerated clinical pitfalls:      
Table 9 
Guidance for combining antiepileptic drugs
10
 
 Establish optimal dose of baseline agent 
 Add drug with multiple mechanisms 
 Avoid combining similar modes of action 
 Titrate new agent slowly and carefully 
33 
 
 Be prepared to reduce dose of original drug 
 Replace less effective drug if response still poor 
 Try range of different duotherapies 
 Add third drug if still sub-optimal control 
 Devise palliative strategy for refractory epilepsy 
 
Pharmacokinetic interactions of the AEDs used should be carefully evaluated, 
especially for drugs affecting hepatic drug metabolizing enzymes
25
 and for the 
elderly who are more likely to be on multiple medications due to the associated 
comorbid illnesses.   
 
Presence of concurrent medical or psychiatric conditions such as depression or 
migraine should be considered carefully. Polytherapy should be better avoided 
during pregnancy, if possible,  especially if it includes Sodium valproate.
26
 
 
Finally, it has to be kept in mind that the patient may be less compliant with a more 
complex regimen. Expenditure for drugs will invariably be greater. Extreme 
caution should be taken to minimize medication errors. 
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Material and Methods 
 
Place of study 
The study was conducted at the Epilepsy Clinic, Institute of Neurology, Madras 
Medical College & Rajiv Gandhi Government General Hospital, a teaching 
institute and 3000 bedded tertiary care hospital situated at Chennai, catering to the 
needs of Northern parts of the state of Tamilnadu and adjoining parts of Andhra 
Pradesh. The patient population includes fair representation from urban and rural 
areas. It includes people from varied socioeconomic strata particularly belonging to 
lower and middle socioeconomic groups. The study population was those patients 
who are attending the Epilepsy Clinic for Antiepileptic Drugs. Institutional ethics 
committee approval was obtained for the study. 
 
Study design and duration 
The study was a cross sectional descriptive study, which was conducted between 
August to December 2013. Everyday approximately 200 to 250 patients attend our 
Epilepsy clinic for Antiepileptic drugs. 200 consecutive patients who met our 
inclusion and exclusion criteria were selected for the study after obtaining 
informed consent. 
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Inclusion Criteria 
1. Epileptic patients who are on combination Antiepileptic drugs for more than a 
year 
2. Those patients who consented to participate in this study after detailed 
explanation in their mother tongue, mostly Tamil. 
3. Those patients with proper treatment records 
 
Exclusion Criteria 
1. Epileptic patients who are on monotherapy 
2. Patients not consented for participating in the study 
3. Patients without proper treatment records 
4. Those with poor drug compliance according to the attenders and patients 
themselves 
5. Patients with major psychiatric illness like schizophrenia and major depression 
 
Methods of data collection 
The eligible patients were identified from patient files and they were enrolled in 
our study after written informed consent. The study objective and process were 
explained to the patients and attenders in their mother tongue for obtaining the 
consent. Patients who consented were interviewed for obtaining relevant data. 
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The data were collected in the proforma specifically designed for the study. The 
data included, 
1. Demographic data: Patient name, age, sex, address, occupation and average 
monthly income were obtained 
2. Disease data: Seizure types, frequency, age of onset and duration, time since last 
seizure, family history of seizure and other comorbid illness were obtained. Seizure 
freedom is defined Freedom from all types of seizures for 12 months or three times 
the preintervention interseizure interval, whichever is longer.
4
 
3. Treatment data: Treatment details including names of the drugs used, starting 
and maximum dosages, duration of treatment, details regarding compliance, 
adverse effects an intake of other medications were recorded 
4. Investigation data: Details of investigations done and their findings were 
recorded, which included EEG, CT Brain, MRI Brain and CSF analysis, complete 
hemogram, blood biochemistry and other relevant investigations. 
 
Methods of data analysis 
All the collected data were entered into Microsoft Windows 2010 excel 
spreadsheet and analyzed with the help of Microsoft excel and SPSS software. 
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Results& Analysis 
200 patients who were found to be eligible and consented for the study were 
recruited from August to December 2013 and analyzed.  
 
Patient characteristics and Demographic profile 
Out of 200 patients 123 (61.5%) were males and remaining 77 (38.5%) were 
females. Mean age of the patients on treatment with Antiepileptic drugs was 
44.56±12.05 years with age ranging from 12 years to 71 years. Mean age of males 
was 43.64±12.41 years with age ranging from 12 years to 71 years; mean age of 
females was 46.01±11.39 years with age ranging from 18 years to 70 years
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Of the 200 patients, 163 (81.5%) were employed, seven (3.5%) were students and 
the remaining 30 (15%) were unemployed. 
 
Majority of the patients were illiterate. Only 15 (7.5%) patients went to college and 
69 (34.5%) were illiterate.  
 
 
 
Clinical characteristics of patients with epilepsy 
Out of 200 patients, 134 (67%) had generalized seizures, 52 (26%) had partial 
seizures with the remaining 14 (7%) had mixed seizure types. Generalized tonic 
clonic seizure was the most common type of seizure which was present in 125 
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(62.5%) patients, followed by absence seizures in 6 (3%), myoclonus in 3 (1.5%), 
simple partial seizures in 15 (7.5%), partial seizure with secondarily generalized 
seizures in 21 (10.5%), Complex partial seizure in 16 (8%) and mixed seizure 
types in 14 (7%) patients. 
 
Mean duration of the seizures was 8.07±5.48 years, ranging from 2 years to 40 
years. 37 (18.5%) patients had duration of seizures < 5 years, 134 (67%) patients 
had seizures between 5 and 10 years, 20 (10%) had seizures between 10 and 20 
years, 9 (4.5%) had seizures > 20 years. 108 (54%) patients were free of seizures 
which is defined as free from seizures for  more than a year as per ILAE 
definition.
4
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33 (16.5%) patients had structural lesions in neuroimaging. Two patients had 
postencephaliticsequalae out of which one of them was on ventriculoperitoneal 
(VP) shunt, 11 patients had gliosis, nine patients had cerebral atrophy, four patients 
had calcified granuloma, three patients had CNS tumors (two gliomas and one 
meningioma), two patients had Mesial temporal lobe sclerosis (MTLS). 
37
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Out of 33 patients with structural lesions, 12 (6%) patients had GTCS, 3 (1.5%) 
had simple partial seizures, 17 (8.5%) had partial seizures with secondary 
generalization and 1 (0.5%) had mixed seizure type. None of the patients with 
complex partial seizures, myoclonus or absence seizures had structural lesions.  
Only 5 patients (4 GTCS, 1 Partial seizure with secondary generalization) with 
structural lesions had seizure freedom. Remaining 28 patients were not under 
seizure control. Table shows the relationship between the presence of structural 
lesions and seizure freedom in various types of seizures. 
 
Electroencephalogram (EEG) abnormalities found in 72 (36%) patients. CSF 
analysis was done in 13 (6.5%) patients, out of which 8 had abnormal findings.  
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Table.10 
Structural 
Lesion 
Seizure type Seizure Freedom Total 
Yes No 
No 
 
 
 
 
 
 
 
 
Absence seizure 3 3 6 
CPS 10 6 16 
GTCS 67 46 113 
Mixed (GTCS/AB) 2 2 4 
Mixed (GTCS/MYO) 7 2 9 
Myoclonus 3 0 3 
Partial seizure with Secondary 
Generalization 
4 0 4 
Simple partial seizure 7 5 12 
Total  103 64 167 
Yes 
 
 
 
 
GTCS 4 8 12 
Mixed (GTCS/MYO) 0 1 1 
Partial seizure with Secondary 
Generalization 
1 16 17 
Simple partial seizure 0 3 3 
Total 5 28 33 
Total 
 
 
 
 
 
 
 
 
Absence seizure 3 3 6 
CPS 10 6 16 
GTCS 71 54 125 
Mixed (GTCS/AB) 2 2 4 
Mixed (GTCS/MYO) 7 3 10 
Myoclonus 3 0 3 
Partial seizure with Secondary 
Generalization 
5 16 21 
Simple partial seizure 7 8 15 
Total 108 92 200 
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40 (20%) patients had comorbid illness, with Diabetes mellitus (DM) in 16 (8%) 
patients,Hypertension in 15 (7.5%), Chronic obstructive pulmonary disease 
(COPD) in 5 (2.5%)and Bronchial asthma in 4 (2%), who were on medications for 
the conditions. 69(34.5%) patients used to consume alcohol regularly.  
 
Pharmacotherapy characteristics 
Phenytoin was the most commonly used AED, which was used in 180 (90%) 
patients, followed by Carbamazepine in 157 (78.5%) patients and Sodium 
valproate in 144 (77%) patients, Phenobarbitone in 7 (3.5%) patients, 
Levetiracetam in 5 (2.5%) patients and Clonazepam in 2 (1%) patients. 
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The mean dosage of Phenytoin was 282 mg/day with dosage ranging from 100 
mg/day to 400 mg/day. Phenytoin dose was suboptimal at 100 mg/day in 12 
patients, of which 10 patients were not under seizure control.  
 
The mean dosage of Carbamazepine was 1052 mg/day with dosage ranging from 
200 mg/day to 1400 mg/day. Carbamazepine dose was suboptimal in 9 patients. 4 
patients were on 200 mg/day and 5 patients were on 300 mg/day. Seizures were not 
controlled in 6 patients. 
 
The mean dosage of Sodium valproate was 1017 mg/day with dosage ranging from 
400 mg/day to 1400 mg/day. Sodium valproate dose was suboptimal at 400 mg/day 
in 17 patients. Seizures were not controlled in 7 patients. 
 
The mean dosage of Phenobarbitone was 80 mg/day with dosage ranging from 60 
mg/day to 120 mg/day. The mean dosage of Levetiracetam was 1400 mg/day with 
dosage ranging from 1000 mg/day to 1500 mg/day. The mean dosage of 
Clonazepam was 0.5 mg/day. 
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Antiepileptic drug prescribing pattern in individual seizure types 
The prescribing pattern of AEDs for the underlying seizure type was appropriate in 
most of the situations except in few cases. Carbamazepine was prescribed as first 
line drug in one patient with absence seizure and one patient with mixed seizure 
having myoclonic seizure. Phenytoin was prescribed as a first line drug in a patient 
myoclonus, another patient with mixed seizure type having absence seizure and in 
three patients with mixed seizure type having myoclonic seizures. 
 
Table.11 
Seizure types Commonest 
drugs 
prescribed  
Second 
commonest drug 
prescribed 
Other drugs 
prescribed 
GTCS PHT CBZ SVP 
Absence seizures SVP PHT CBZ 
Simple partial seizure CBZ PHT SVP 
Partial seizure with sec. 
generalization 
CBZ PHT SVP 
Complex partial seizure CBZ SVP PHT 
Myoclonic epilepsy SVP PHT CBZ 
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Pattern of Antiepileptic drug combinations 
113 (56.5%) Patients were on double AED therapy. 79 (39.5%) patients were on 
three drug AED therapy and 8 (4%) patients were on four drug AED therapy. 
 
Double Antiepileptic drug combinations 
 
Out of the 113 patients on two drug AED therapy, 55 patients were on Phenytoin 
and Carbamazepine  duotherapy, which was the most common combination 
duotherapy. The other duotherapy combinations are Phenytoin and Sodium 
valproate (39 patients) and Carbamazepine and Sodium valproate (19 patients). 34 
patients on duotherapy containing Phenytoin and Carbamazepine had seizure 
freedom for more than a year. 25 patients on duotherapy containing Phenytoin and 
Sodium valproate had seizure freedom for more than a year. 11 patients on 
duotherapy containing Sodium valproate and Carbamazepine had seizure freedom 
55
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for more than a year. Three out of 55 patients on Phenytoin and Carbamazepine 
combination and two out of 19 patients on Carbamazepine and Sodium valproate 
combination had structural lesions in neuroimaging.  
 
 
 
Table.12 Comparision of Seizure freedom in two drug AED Combination  
Combination Seizure freedom Total  
Yes No 
PHT+SVP 25 14 39 
 GTCS 20 
Absence 1 
Myoclonus 1 
Simple partial 0 
CPS 0 
Partial with sec gen 0 
Mixed 3 
GTCS 13 
Absence 1 
Myoclonus 0 
Simple partial 0 
CPS 0 
Partial with sec gen 0 
Mixed 0 
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PHT+CBZ 34 21 55 
 GTCS 26 
Absence 0 
Myoclonus 0 
Simple partial 3 
CPS 3 
Partial with sec gen 2 
Mixed 0 
GTCS 15 
Absence 0 
Myoclonus 0 
Simple partial 3 
CPS 1 
Partial with sec gen 2 
Mixed 0 
 
CBZ+SVP 11 8 19 
 GTCS 1 
Absence 0 
Myoclonus 0 
Simple partial 3 
CPS 3 
Partial with sec gen 1 
Mixed 3 
GTCS 0 
Absence 1 
Myoclonus 0 
Simple partial 0 
CPS 5 
Partial with sec gen 2 
Mixed 0 
 
Total  70 43 113 
 
 
Chi Square test 
 Value df Asymp. Sig (2 sided) 
Pearson Chi-Square 0.210 2 0.900 
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Triple Antiepileptic drug combinations 
 
79 patients were on AED combinations containing three drugs. 74 patients were on 
Phenytoin, Carbamazepine and Sodium valproate combination, which was the 
most common triple AED combination. 4 patients were on Phenytoin, Sodium 
valproate and Phenobarbitone combination. One patient was on Phenytoin, 
Carbamazepine and Phenobarbitone combination. Out of 74 patients on Phenytoin, 
Carbamazepine and Sodium valproate combination 25 patients had structural 
lesions in neuroimaging. One patient had structural lesion in the Phenytoin, 
Sodium valproate and Phenobarbitone combination. 34 patients had adequate 
control with seizure freedom for more than a year. 30 out of 74 patients on 
Phenytoin, Carbamazepine and Sodium valproate combination, 3 out of 4 patients 
on Phenytoin, Sodium valproate and Phenobarbitone combination and the single 
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patient on Carbamazepine, Sodium valproate and Phenobarbitone combination had 
seizure freedom for more than a year. 
 
Table.13 Comparision of Seizure freedom in 3 drug AED Combinations 
Combination Seizure freedom Total 
YES NO 
PHT+CBZ+SVP 30 44 74 
 GTCS 17 
Absence 2 
Myoclonus 2 
Simple partial 1 
CPS 4 
Partial with sec gen 2 
Mixed 2 
GTCS 21 
Absence 1 
Myoclonus 0 
Simple partial 5 
CPS 0 
Partial with sec gen 12 
Mixed 5 
 
PHT+CBZ+PB 1 (GTCS 1) 0 1 
PHT+SVP+PB 3 (GTCS 3) 1 (GTCS 1) 4 
Total 34 45 79 
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Chi-Square tests 
 Value df Asymp. Sig. (2 sided) 
Pearson Chi-Square 3.179 2 0.204 
 
Four Antiepileptic drug combinations 
 
Eight patients were on four drug AED combinations. The most common 
combination being Phenytoin, Carbamazepine, Sodium valproate and 
Levetiracetam taken by four patients. Two patients were on Phenytoin, 
Carbamazepine, Sodium valproate and Phenobarbitone combination. One each in 
Phenytoin, Carbamazepine, Sodium valproate, Clonazepam and Carbamazepine, 
Sodium valproate, Levetiracetam, Clonazepam combinations respectively. Two 
patients had structural lesions.  
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Table.14 Comparison of Seizure freedom in 4 drug AED Combination  
Combination Seizure freedom Total 
Yes No 
PHT+CBZ+SVP+CLO 0 1 (GTCS 1) 1 
PHT+CBZ+SVP+PB 1 (GTCS 1) 1 (GTCS 1) 2 
PHT+CBZ+SVP+LEV 2 (GTCS 2) 2(GTCS 2) 4 
CBZ+SVP+LEV+CLO 1 (Mixed 1) 0 1 
Total 4 4 8 
 
Chi-Square test 
 Value df Asymp. Sig. (2 sided) 
Pearson Chi-Square  2.000 3 0.572 
 
 
Four patients were on adequate control with seizure freedom for more than a year. 
Two patients were on Phenytoin, Carbamazepine, Sodium valproate and 
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Levetiracetam combination. One each in Phenytoin, Carbamazepine, Sodium 
valproate, Phenobarbitone combination and Carbamazepine, Sodium valproate, 
Levetiracetam, Clonazepam combinations respectively. 
 
Pattern of Adverse effects 
 
 
 
Sedation
Gum 
hypertrophy
Somnolence Nausea Vomiting Giddiness Wt gain
PHT 11 2 11 4 5
CBZ 5 11 9 6
SVP 6 5 5 7 1 7
PB 1 1
LEV 2
CLON 1
0
2
4
6
8
10
12
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The most common adverse effects were somnolence in 28 (14%) patients, sedation 
in 24 (12%), nausea 20 (10%), vomiting 18 (9%), weight gain 7 (3.5%), gum 
hypertrophy 2 (1%) and giddiness 1 (0.5%), in the order of decreasing frequency.  
 
33 out of 180 patients (18%) on Phenytoin had adverse effects. Sedation and 
somnolence (11 patients each) was the most common side effects in patients on 
Phenytoin, followed by vomiting (5 patients), nausea (4 patients) and gum 
hypertrophy (1 patient).  
 
31 out of 157 (20%) patients on Carbamazepine had adverse effects. Somnolence 
(11 patients) was the most common adverse effect, followed by nausea (9 patients), 
vomiting (6 patients) and sedation (5 patients).  
 
31 out of 144 patients on Sodium valproate had adverse effects. Weight gain and 
vomiting (7 patients each) were the most common adverse effects, followed by 
sedation (6 patients), nausea and somnolence (5 patients each) and giddiness (1 
patient).Sedation and somnolence (1 patient each) were the side effects in patients 
on Phenobarbitone, nausea was present in 2 patients on Levetiracetam and sedation 
was present in one patient on Clonazepam. No patient had life threatening adverse 
events. 
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Table.15  
Patient characteristics and Demographic profile 
Parameters  Classification  N (%)  
Total patients=200 
Gender  Male 123 (61.5%) 
Female  77 (38.5%) 
Age (Years) Mean ± SD, Range 44.56±12.05, 12-71 years 
Mean ± SD, Range 
(Male) 
43.64±12.41, 12-71 years 
Mean ± SD, Range 
(Female) 
46.01±11.39, 18-70 years 
Employment  Employed 163 (81.5%) 
Unemployed 30 (15%) 
Student  7 (3.5%) 
Educational status Primary school 56 (28%) 
High school 58 (29%) 
Higher school 2 (1%) 
College  15 (7.5%) 
Illiterate 69 (34.5%) 
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Table.16 
Clinical characteristics of patients with Epilepsy 
 
Disease characteristics Description  N (%)  
Total patients=200 
Types of Seizures Generalized seizures 134 (67%) 
GTCS 125 (62.5%) 
Absence seizure 6 (3%) 
Myoclonic seizures 3 (1.5%) 
Partial seizures 52 (26%) 
Simple partial seizure 15 (7.5%) 
Partial seizure with 
secondary generalization 
21 (10.5%) 
Complex partial seizure 16 (8%) 
Mixed seizures 14 (7%) 
Duration of Seizures Mean±SD, Range 8.07±5.48, 2-40 years 
< 5 years 37 (18.5%) 
5-10 years 134 (67%) 
10-20 years 20 (10%) 
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>20 years 9 (4.5%) 
Seizure freedom Yes (>1 years) 108 (54%) 
Without structural lesions 103/167 (62%) 
With structural lesion 5/33 (15%) 
No (<1 year) 92 (46%) 
Structural lesions Present 33 (16.5%) 
Gliosis  11 (5.5%) 
Cerebral atrophy 9 (4.5%) 
Calcified granuloma 4 (2%) 
CNS tumors 3 (1.5%) 
MTLS 2 (1%) 
Absent  167 (83.5%) 
Electroencephalogram 
(EEG) 
Abnormal 72 (36%) 
Comorbid illness DM 16 (8%) 
HT 15 (7.5%) 
COPD 5 (2.5%) 
BA 4 (2%) 
Alcohol consumption  Yes  69 (34.5%) 
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Table.17 
Pharmacotherapy characteristics 
Pharmacotherapy 
characteristics 
Description  N (%)  
Total patients=200 
Frequency of AED 
usage 
PHT 180 (90%) 
CBZ 157 (78.5%) 
SVP 144 (77%) 
PB 7 (3.5%) 
LEV 5 (2.5%) 
CLO 2(1%) 
Doasage , Mean and 
Range 
PHT 282 mg/d, 100-400 mg/d 
CBZ 1052 mg/d, 200-1400 
mg/d 
SVP 1017 mg/d, 400-1400 
mg/d 
PB 80 mg/d, 60-120 mg/d 
LEV 1400 mg/d, 1000-1500 
mg/d 
CLO 0.5 mg/d 
2 drug AED 
Combinations (113 
Patients) 
PHT+CBZ 55 (49%) 
PHT+SVP 39 (34%) 
CBZ+SVP 19 (17%) 
Seizure freedom 70 (62%) 
PHT+CBZ 34 
PHT+SVP 25 
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CBZ+SVP 11 
3 drug AED 
Combinations (79 
Patients) 
PHT+CBZ+SVP 74 (94%) 
PHT+SVP+PB 4 (5%) 
PHT+CBZ+PB 1 (1%) 
Seizure freedom 34 (43%) 
PHT+CBZ+SVP 30 
PHT+SVP+PB 3 
PHT+CBZ+PB 1 
4 drug AED 
Combinations  
(8 Patients) 
PHT+CBZ+SVP+LEV 4 (50%) 
PHT+CBZ+SVP+PB 2 (25%) 
PHT+CBZ+SVP+CLO 1 (12.5%) 
CBZ+SVP+LEV+CLO 1 (12.5%) 
Seizure freedom 4 (50%) 
PHT+CBZ+SVP+LEV 2 
PHT+CBZ+SVP+PB 1 
PHT+CBZ+SVP+CLO 0 
CBZ+SVP+LEV+CLO 1 
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Discussion 
Epilepsy is one of the most common neurological illnesses with the same burden as 
lung cancer in men and breast cancer in women.
27
 Studies in recent years have 
provided more insight into the seizure pathophysiology and management. The 
ultimate goal of treating epilepsy is adequate control of seizures without side 
effects. The objective of our study is to analyze the combination Antiepileptic 
drugs used for managing epilepsy in a tertiary care hospital in South India. 
Majority of the patients in our study were in their middle age. The mean age was 
44.56 years. Males were slightly younger than females, with mean age of males 
was 43.64 years and that of females was 46.01 years. The age distribution across 
other Indian studies were variable, however most patients were between 20-40 
years of age.
28,29
Sridharan and Murthy undertook a meta-analysis of the prevalence 
data obtained from 20 community-based studies on epilepsy in India. According to 
their analysis, age-specific prevalence rates were higher in second decade for males 
and third and fourth decades for females.
30
 Our patients were slightly older 
compared to other Indian studies.  
Like other Indian studies,
29,30,31
 the majority of the patients were males (123 
patients). Though employment opportunities are affected in patients with epilepsy 
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due to social stigma and danger of accidents in workplace, particularly in 
dangerous jobs like driving, working with machinery, our patients had good 
employment rate of 81.5%. One third of the patients attending the epilepsy clinic 
were illiterate (34.5%). Diabetes mellitus and hypertension were the commonly 
associated comorbid conditions. 
The incidence of generalized seizures varies between 45% and 86% in various 
Indian studies. In our study Idiopathic generalized seizures were the most common 
seizure type (61%) than partial seizures, a result consistent with many other Indian 
studies.
29,30,31
Structural lesions were present in 16.5% of patients and it was higher 
among the patients with partial seizures. Gliosis was the most common structural 
lesion found in the neuroimaging. Majority of patients had seizure duration 
between 5 and 10 years with mean duration around 8 years. 54% of patients were 
free from seizure at the time of analysis, which is comparable to other Indian 
studies. In a study conducted at Sri ChitraTirunal Institute Medical Sciences, 
seizure control rate was similar.
28
 Seizure control was poor in patients with 
structural lesions. Only 15% of patients with structural lesions had seizure control, 
whereas 62% of patients without structural lesions had seizure freedom. This is 
consistent with other studies which also show poor seizure control in patients with 
structural lesions.
20,32
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GTCS was the most common type of seizure, seen in 125 patients (62.5%). 71 
patients (57%) with GTCS had good seizure control with the combinbation AEDs. 
Phenytoin was used as the first line drug in 111 patients (55.5%), in which 62 
patients (56%) had good seizure control. Carbamazepine and Sodium valproate 
was used in 6 and 8 patients respectively. Phenytoin and Carbamazepine 
combination was the most commonly used combination in 41 patients, followed by 
Phenytoin, Carbamazepine and Sodium valproate used in 38 patients and 
Phenytoin, Sodium valproate in 33 patients. 
Partial seizure with secondary generalization was the next common type of seizure, 
which was present in 21 patients (10.5%). Carbamazepine was used as the first line 
drug in 19 patients (90%). Only 5 patients (24%) had seizure control, probably 
reflecting underlying structural lesions in many of them (17 patients). Phenytoin, 
Carbamazepine and Sodium valproate combination is used in 14 patients, with 
only two of them under seizure control. 
Complex partial seizure was next in frequency, which was present in 16 patients 
(8%). Carbamazepine was used in 15 patients with one patient on Phenytoin. 9 out 
of 15 patients on CBZ and the only patient on PHT had good seizure 
control.Sodium valproate and Carbamazepine was used in 8 patients. Four patients 
were on Carbamazepine and Phenytoin combination. 
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Simple partial seizure was seen in 15 patients (7.5%). All of them were on 
Carbamazepine. 7 (47%) of them had good seizure control. 6 each were on 
Carbamazepine with phenytoin and Carbamazepin, Phenytoin and Sodium 
valproate combination. 
Mixed seizure type was seen in 14 patients (7%), which included GTCS associated 
with either absence seizure or myoclonus. Sodium valproate was the commonly 
used AED. It was used in 9 patients. 4 patients were on Phenytoin and one on 
Carbamazepine. Seizure control was obtained in 4 out of 9 patients (45%) treated 
with SVP. Sodium valproate, phenytoin and carbamazepine was used in 7 patients. 
Absence seizure was present in 6 patients (3%). 5 patients were on Sodium 
valproate, the remaining patient was on Carbamazepine. 3 patients (50%) had 
seizure control. Sodium valproate, Phenytoin and Carbamazepine combination was 
used in 3 patients. 
Myoclonus was seen in 3 patients. Two patients were on Sodium valproate and one 
on Phenytoin. All the three were under good control. 
Overall the drugs were prescribed according to underlying seizure types most of 
the times. Carbamazepine was used as the common first line drug in partial 
seizures, Sodium valproate in absence and myoclonic seizures and Phenytoin was 
preferred in generalized tonic clonic seizures. However one patient with absence 
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seizure was on Carbamazepine, one patient with myoclonus was on Phenytoin, one 
patient CPS was on Phenytoin and five patients with mixed seizures were on 
Phenytoin or Carbamazepine. These are not the first line drugs for the above 
conditions, infact some of them are contraindicated. 
Phenytoin, Carbamazepine, Sodium valproate and Phenobarbitone are the 
commonly available antiepileptic drugs in our hospital. Treatment is provided free 
of cost for patients and the newer antiepileptics are not widely available in our 
hospital. Hence, majority of Antiepileptic drug combinations contain first 
generation antiepileptics only. 
According to the current knowledge regarding the rational combination of 
antiepileptic drugs, it has been postulated that antiepileptic drugs with different 
mechanisms of action are superior to drugs with similar mechanism of action.
18
 
Because AEDs with similar mechanism of action will have similar side effect 
profiles, it will result in additive side effects leading to poor compliance or drug 
withdrawal. The most successful observed AED combination is single mechanism 
drug combined with a drug that possesses multiple mechanisms of action. This 
observation is exemplified by the consistent synergistic performance of the 
combination of Lamotrigene and Sodium valproate in epileptics.
10
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Conventional AEDs (PHT,CBZ, PB,VPA) recorded the highest frequency of use 
across many Indian studies. Phenytoin was the commonest drug used in 60% of 
patients and Sodium valproate in 21% of patients in a study conducted at a 
teaching hospital in Hyderabad .
33
In another Indian study done at Delhi by 
AhsanHaroon and ManjariTripathi, et al
31
 Sodium valproate (38%) was the most 
common conventional drug used as first line, followed by Carbamazepine (31%) 
and Phenytoin (20%). Phenytoin was the most common drug used in our study. It 
was followed by the usage of Carbamazepine and Sodium valproate, 
Phenobartbitone, Levetiracetam and Clonazepam in various combinations. 
Phenytoin and Carbamazepine have similar mechanisms of action, blockade of 
sodium channels. Sodium valproate has multiple mechanisms of action. 
Phenobarbitone and Clonazepam acts through facilitation of GABAergic 
inhibition. Levetiracetam acts through modulation of synaptic vesicle protein SV2.  
As per the current knowledge, combining Phenytoin or Carbamazepine with 
Sodium valproate will be beneficial, rather than combining Phenytoin and 
Carbamazepine. In a study conducted by Brodie and Stephen
34
 in Scotland, 2881 
patients were studied and 332 patients were on combination AEDs. 
Lamotrigene/Sodium valproate  was the commonest successful duotherapy 
regimen which was used in 55 patients. Phenytoin/Phenobarbitol was the second 
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most common used in 29 patients and Phenytoin/Carbamazepine combination was 
found in 13 patients.  
In our study Phenytoin with Carbamazepine was the most common double drug 
combination. It was used by 49% of patients who were on double AED therapy. 
62% of patients on the combination had good seizure control. 31% of patients in 
the combination had some form of minor adverse effects, the most common being 
sedation. Though both the drugs have same mechanism of action which is 
considered to be an irrational combination, our patients had seizure control and 
adverse events profile similar to double drug combinations containing drugs with 
different mechanisms of action.
34
 
Phenytoin with Sodium valproate was the second most common double drug 
combination. It was used by 35% of patients on double AED therapy. 64% of 
patients on the combination had good seizure control. 31% of patients on the 
combination had some form of adverse effects, the most common being sedation 
and vomiting. 
Carbamazepine with Sodium valproate was the third most common double drug 
combination, taken by 17% of patients on double AEDs. 58% of patients had good 
seizure control. 32% of patients had some adverse effects, the most common being 
nausea. 
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Phenytoin/Lamotrigene/Topiramate was the commonest effective three drug 
combination in the by Brodie and Stephen.
34
 in our study Phenytoin, 
Carbamazepine and Sodium valproate was the commonest triple drug therapy, 
taken by 94% of patients. 41% had good seizure control. 40% of patients had some 
adverse effects. 
Phenytoin, Sodium valproate and Phenobarbitonewas the second most common 
triple drug combination, taken only by 5% of patients on triple therapy. 75% had 
good seizure control. 50% of (2 patients) patients had some form of adverse 
effects. 
Phenytoin, Carbamazepine and Phenobarbitone was the least commonly used triple 
drug combinations, taken by 1% of patients. The patient had good seizure control 
and had minor adverse effect like somlonence. 
In four drug AED combinations, Phenytoin, Carbamazepine, Sodium valproate and 
Levetiracetam was used in 4 (50%) patients, and seizure control was obtained in 2 
(50%) patients. 3 patients (75%) had minor side effects. 
Only two patients were on Phenytoin, Carbamazepine, Sodium valproate and 
Phenobarbitone combination, with seizure control in one patient and minor adverse 
effects in both the patients. 
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In other 2 four drug combinations containing Phenytoin, Carbamazepine, Sodium 
valproate, Clonazepam and Carbamazepine, Sodium valproate, Levetiracetam, 
Clonazepam, seizures were controlled in the latter combination, with both having 
minor adverse effects. 
There was no five or more drug combintions in our study.  
Overall, 54% of patients treated with combination Antiepileptic drugs were free 
from seizure for more than a year, defined as seizure freedom.
4
 The majority of 
patients under seizure freedom just took two AED combinations.
31,34
All the 3 
double drug combinations had similar efficacy in seizure control, around 60% of 
patients taking the particular combinations. In triple drug combinations, only 
Phenytoin, Carbamazepine and Sodium valproate combination was taken by 
majority of patients (94%). Seizure control was relatively poor compared to double 
drug therapies. Only 41% had good seizure control compared to double drug 
combinations. Other three drug and four drug combinations were taken only by 
few patients. Hence their seizure control and adverse effect profiles could not give 
much information for analysis. 
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Conclusion 
This cross-sectional study examined demographic profile, disease characteristics 
and prescribing pattern of antiepileptic drugs in 200 epileptic patients on 
combination antiepileptic drugs in a tertiary care hospital in Chennai, Tamilnadu. 
 
1. Majority was middle aged educated (65.5%) and employed (81.5%) males 
(61.5%). 
2. Idiopathic generalized seizures were more common (61%) than partial 
seizures. 
3. Structural lesions were present in 16.5% of patients and they had poor 
seizure control. 
4. More than half of the patients were treated with two drug AED 
combinations. 56.5% of patients were maintained on double drug 
combinations, 39.5% on three drug and 4% on four drug combinations. No 
combination had more than four drugs. 
5. Phenytoin was the commonly used antiepileptic drug in various 
combinations, Phenytoin and Carbamazepine were the commonly used 
double AED combination regimen, Phenytoin, Carbamazepine and Sodium 
valproate were the commonly used three drug AED combination regimen. 
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6. Antiepileptic drugs of choice for generalized seizures and partial seizures 
were used in accordance with the recommended guidelines. 
7. Though majority of the patients were maintained on older antiepileptics, 
their efficacy in controlling seizures were comparable to newer 
antiepileptics. In cost constrained situations older AEDs are as effective as 
newer and more costlier AEDs. 
8. Though AEDs with similar mechanisms of action are generally not preferred 
due to the concern of additive side effects, they were as effective as other 
combinations with different mechanisms of action. The adverse events were 
also comparable. 
9. Overall, 54% of patients had good seizure control with the combination 
AEDs. Seizure control was better with two drug combinations than that of 
three and four drug combinations 
10. 50% of patients reported at least one minor adverse event, which did not 
require change of drugs. Adverse events were more common with three and 
four drug combinations than two drug combinations. 
 
Polytherapy remains the mainstay of treatment for large proportion of epileptic 
patients, particulalrly in cases of refractory epilepsy. Rational ploytherapy is a 
difficult to achieve and elusive goal with the knowledge available at present. It 
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needs further research to find the ideal AED combinations. Treatment decision has 
to be made on an individual basis to make the polytherapy a successful one. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
72 
 
Bibliography  
1. World Health Organisation. WHO | Epilepsy. WHO Factsheet (2012). at 
<http://www.who.int/mediacentre/factsheets/fs999/en/> 
2. Indian Epilepsy Society. Indian epilepsy society guideline.pdf. (2008). 
3. Fisher, R. et al. An Operational Clinical Definition of Epilepsy. 
4. Kwan, P. et al. Definition of drug resistant epilepsy: consensus proposal by 
the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. 
Epilepsia51, 1069–77 (2010). 
5. Berg, A. T. et al. Revised terminology and concepts for organization of 
seizures and epilepsies: report of the ILAE Commission on Classification and 
Terminology, 2005-2009. Epilepsia51, 676–85 (2010). 
6. Proposal for Revised Clinical and Electroencephalographic Classification of 
Epileptic Seizures. Epilepsia22, 489–501 (1981). 
7. Proposal for Revised Classification of Epilepsies and Epileptic Syndromes. 
Epilepsia30, 389–399 (1989). 
8. Bromfield EB, Cavazos JE, S. J. in An Introd. to Epilepsy (2006). 
73 
 
9. Morrell, M. J. Antiepileptic Medications for the Treatment of Epilepsy. 
Semin. Neurol.22, 247–258 (2002). 
10. Brodie, M. J. & Sills, G. J. Combining antiepileptic drugs--rational 
polytherapy? Seizure20, 369–75 (2011). 
11. Stephen, L. J. & Brodie, M. J. Antiepileptic drug monotherapy versus 
polytherapy : pursuing seizure freedom and tolerability in adults. Curr. 
Opin. Neurol.25, 164–172 (2012). 
12. Williom O Tatum, IV. Antiepileptic drugs : adverse effects and drug 
interactions. Contin. Lifelong Learn. Neurol.16, 136–158 (2010). 
13. NICE Clinical Guidelines. The epilepsies : the diagnosis and management 
of the epilepsies in adults and children in primary and secondary care. 
14. American Academy of Neurology. Practice Parameter: A guideline for 
discontinuing antiepileptic drugs in seizure-free patients--Summary 
Statement. Neurology47, 600–602 (1996). 
15. Camfield, P. & Camfield, C. When is it safe to discontinue AED treatment? 
Epilepsia49 Suppl 9, 25–8 (2008). 
74 
 
16. Fountain, N. B. Choosing among antiepileptic drugs. Contin. Lifelong Learn. 
Neurol.16, 121–135 (2010). 
17. Shorvon, S. D. The etiologic classification of epilepsy. Epilepsia52, 1052–7 
(2011). 
18. Lee, J. W. & Dworetzky, B. Rational Polytherapy with Antiepileptic Drugs. 
Pharmaceuticals3, 2362–2379 (2010). 
19. Shorvon, S. D., Chadwick, D., Galbraith, A. W. & Reynolds, E. H. One drug 
for epilepsy. Br. Med. J.1, 474–476 (1978). 
20. Kwan, P. & Brodie, M. J. Early identification of Refractory Epilepsy. N. 
Engl. J. Med.342, 314–319 (2000). 
21. Peltola J, Peltola M, Raitanen J, et al. Seizure-freedom with combination 
therapy in localization-related epilepsy. Seizure 276–280 (2008). 
22. Cereghino, J. J. et al. The efficacy of carbamazepine combinations in 
epilepsy. Clin. Pharmacol. Ther.18, 733–41 (1975). 
23. Duncan, J. S., Shorvon, S. D. & Trimble, M. R. Effects of Removal of 
Phenytoin, Carbamazepine, and Valproate on Cognitive Function. 
Epilepsia31, 584–591 (1990). 
75 
 
24. Campillos, M., Kuhn, M., Gavin, A.-C., Jensen, L. J. & Bork, P. Drug target 
identification using side-effect similarity. Science321, 263–6 (2008). 
25. Perucca, E. & Kwan, P. Overtreatment in epilepsy: how it occurs and how it 
can be avoided. CNS Drugs19, 897–908 (2005). 
26. Artama, M., Auvinen, A., Raudaskoski, T., Isojärvi, I. & Isojärvi, J. 
Antiepileptic drug use of women with epilepsy and congenital malformations 
in offspring. Neurology64, 1874–8 (2005). 
27. Perucca, E. & Tomson, T. The pharmacological treatment of epilepsy in 
adults. Lancet Neurol.10, 446–56 (2011). 
28. Thomas, S., Koshy, S., Sudhakaran Nair, C. & Sarma, S. Frequent seizures 
and polytherapy can impair quality of life in persons with epilepsy. Neurol. 
India53, 46 (2005). 
29. Das. Neuroepidemiology of major neurological disorders in rural Bengal. 
Neurol. India44, 47 (2003). 
30. Sridharan, R. & Murthy, B. N. Prevalence and pattern of epilepsy in India. 
Epilepsia40, 631–6 (1999). 
76 
 
31. Haroon, A., Tripathi, M., Khanam, R. & Vohora, D. Antiepileptic drugs 
prescription utilization behavior and direct costs of treatment in a national 
hospital of India. Ann. Indian Acad. Neurol.15, 289–93 (2012). 
32. Semah, F. et al. Is the underlying cause of epilepsy a major prognostic factor 
for recurrence? Neurology51, 1256–62 (1998). 
33. Mathur, S., Sen, S., Ramesh, L. & Sathish Kumar, M. Utilization pattern of 
antiepileptic drugs and their adverse effects , in a teaching hospital. 3, 55–59 
(2010). 
34. Stephen, L. J. & Brodie, M. J. Seizure freedom with more than one 
antiepileptic drug. Seizure11, 349–351 (2002).  
 
 
 
 
 
 
 
 
77 
 
Annexures  
List of abbreviations 
AED Antiepileptic drug 
CBZ Carbamazepine 
CPS Complex partial seizure 
CZP Clonazepam 
EEG Electroencephalogram 
ESX Ethosuximide 
FBM Felbamate 
GBP Gabapentin 
GTCS Generalized tonic clonic seizure 
ILAE International league against epilepsy 
LEV Levetiracetam 
LTG Lamotrigene 
NICE  National Institute of Health and Care Excellence 
OXC Oxcarbazepine 
PB Phenobarbitone 
PHT Phenytoin 
SVP/VPA Sodium valproate/ Valproaic acid 
TGB Tiagabine 
TPM Topiramate 
VIG Vigabatrin 
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PROFORMA 
Analysis of Antiepileptic Drug Combinations in Patients with Epilepsy 
 
Name :Date: 
Age/Sex:                                                   OP/IP No: 
Weight:        MIN No: 
Occupation: 
Income: 
Address: 
Phone number: 
Educational status: 
Seizure type(s) 
S.No Seizure type Duration 
1 GTCS  
2 Simple partial seizure  
3 Complex partial seizure  
4 Partial seizure with secondary 
generalization 
 
5 Mixed  
 
Time since last seizure: 
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Antiepileptic drugs used: 
Polytherapy: 
 AED1 AED2 AED3 AED4 
Date of initiation     
Duration     
Starting dose     
Maintenance 
dose 
    
Seizure freedom     
Adverse effects     
Compliance     
Reason for poor 
compliance 
    
Reason for 
changing/adding  
the AED 
    
 
Drug history (other than AED): 
Menstrual history: 
Personal History: 
 Smoking: 
 Alcohol: 
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Sleep pattern: 
 Other: 
Comorbid illness: 
 SHT: 
 DM: 
CAD: 
 PT: 
HIV/Syphilis: 
 Others: 
Family history: 
 Marital status: 
No of children: 
General examination: 
CNS examination: 
Investigations: 
 EEG: 
 
 CT Brain: 
 
 MRI Brain/hippo: 
 
 CSF Analysis: 
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INFORMATION SHEET 
 
 We are conducting a study “Analysis of the antiepileptic drug combinations 
in patients with epilepsy” at the Institute of Neurology, Rajiv Gandhi Govt. 
General Hospital, Chennai. The purpose of this study is to analyse the use of 
antiepileptic drug combinations in patients with epilepsy and its rationality with 
regard to seizure type, seizure control, drug interactions and adverse effects. 
 
 The privacy of the patients in the research will be maintained throughout the 
study. In the event of any publication or presentation resulting from the 
research, no personally identifiable information will be shared. 
 
 Taking part in this study is voluntary. You are free to decide whether to 
participate in this study or to withdraw at any time. Your decision will not result 
in any loss of benefits to which you are otherwise entitled. 
 
  The results of the study may be intimated to you at the end of the study period 
or during the study if anything is found abnormal which may aid in the 
management or treatment. 
 
 
Signature of the investigator                       Signature of the participant 
 
Date: 
 
 
82 
 
PATIENT CONSENT FORM 
Study Details : “Analysis of Antiepileptic drug combinations in  
patients with epilepsy” 
 
Study Centre  : Institute of Neurology, 
Madras Medical College and  
                                    Rajiv Gandhi Government General Hospital,  
   Chennai - 600 003. 
 
Patient may check ( ) these boxes: 
 
I confirm that I have understood the purpose of procedure for the above study. I 
have the opportunity to ask question and all my questions and doubts have been 
answered to my complete satisfaction. 
 
I understand that my participation in the study is voluntary and that I am free to 
withdraw at any time without giving reason, without my legal rights being affected. 
 
I understand that the investigator of the clinical study, others working on his 
behalf, the ethical committee and the regulatory authorities will not need my permission 
to look at my health records, both in respect of current study and any further research 
that may be conducted in relation to it, even if I withdraw from the study. However, I 
understand that my identity will not be revealed in any information released to third 
parties or published, unless as required under the law. I agree not to restrict the use of 
any data or results that arise from this study. 
 
I agree to take part in the above study and to comply with the instructions given 
during the study and faithfully cooperate with the study team and to immediately 
inform the study staff if I suffer from any deterioration in my health or well being or 
any unexpected or unusual symptoms. 
 
I hereby give permission to undergo complete clinical examination and 
diagnostic tests including hematological, biochemical, radiological, EMG, EEG, NCS, 
Lumbar puncture and muscle biopsy, appropriate to the clinical diagnosis. 
 
 I hereby consent to participate in this study. 
 
Signature / Thumb impression:               Place :                  Date : 
 
 
Patient Name and Address:    
 
Signature of Investigator:                        Place :                    Date : 
 
Study Investigator’s Name :   
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Master Chart 
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